CLN-978, a novel half-life extended CD19/CD3/HSA-specific T cell-engaging antibody construct with potent activity against B-cell malignancies with low CD19 expression.
Kristan A MeetzeNaveen K MehtaBochong LiJennifer S MichaelsonPatrick A BaeuerlePublished in: Journal for immunotherapy of cancer (2023)
CLN-978 warrants further exploration. An ongoing clinical phase 1 trial is investigating safety, pharmacokinetics, pharmacodynamics, and the initial therapeutic potential of subcutaneously administered CLN-978 in patients with non-Hodgkin's lymphoma.